DBS in Toxicology: “Can Science Overcome the Regulatory Challenge?”

If you can't see this e-bulletin, click here

Algorithme Pharma logo  

eBulletin  |  April 2014

Dedicated Individual Service - Unique Full Service Provider Focused on Early Stage Clinical Research

DBS in Toxicology: “Can Science Overcome the Regulatory Challenge?”

Dried Blood Spot (DBS) analysis can provide significant advantages in drug development as it reduces blood sampling volumes, improves data quality and reduces costs. At the recent Society of Toxicology (SOT) Annual Meeting, Dr. Fabio Garofolo, Vice-President Bioanalytical Services, Algorithme Pharma, presented on DBS analysis and highlighted the Pre-Cut technique for use in analyzing New Molecular Entities (NME) and Biomarkers. 

image of Dr. Fabio Garofolo

Click here to view the Case Study Poster

Attendees were provided with three Case Studies demonstrating methods which overcome current DBS issues, such as hematocrit impact, dilution effect, internal standard techniques and stability considerations. With this approach taken, DBS can be used as an effective sampling technique, leading to regulatory agency acceptance.

Algorithme Pharma logo
For more information, please contact us at:
1 (450) 973-6077
1 (888) 267-7449
contact@algopharm.com View our Poster Podcast on Youtube